证券代码：603880 证券简称：ST南卫 公告编号：2023-078 江苏南方卫材医药股份有限公司 关于归还暂时补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江苏南方卫材医药股份有限公司（以下简称"公司"）于2022年12月9日召开了公司 第四届董事会第六次会议和第四届监事会第五次会议，审议通过了《关于使用部分闲置 募集资金暂时补充流动资金的议案》，同意公司使用江苏南方卫材医药股份有限公司募集 资金专户闲置募集资金人民币7,000万元暂时补充流动资金，使用期限自董事会审议通过 之日起不超过12个月。独立董事、监事会对上述事项发表了同意意见,保荐机构出具了核 查意见。具体内容详见公司于2022年12月10日在上海证券交易所网站披露的《江苏南方 卫材医药股份有限公司关于使用部分闲置募集资金暂时补充流动资金的公告》（公告编 号：2022-059）。 截至2023年9月4日，公司已将实际用于暂时补充流动资金的7,000万元募集资金全部 归还至募集资金专项账户，公司在使用部分闲置募集资金暂时补充流 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥352,868,398.82, representing a 37.99% increase compared to ¥255,712,885.01 in the same period last year[19]. - Net profit attributable to shareholders for the first half of 2023 was ¥7,900,369.63, up 26.67% from ¥6,236,905.15 in the previous year[19]. - The basic earnings per share increased by 50.00%, from ¥0.02 to ¥0.03[19]. - The weighted average return on net assets rose to 1.27%, an increase of 0.31 percentage points compared to 0.96% in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥8,130,725.24, reflecting a 39.57% increase from ¥5,825,713.98 in the same period last year[19]. - The company reported a significant increase in operating costs, which rose by 43.28% to RMB 297.45 million, primarily due to increased material costs and depreciation of fixed assets[51]. - The company reported a revenue of 50 million USD, an increase from 43.48 million USD, reflecting a growth of approximately 15.5%[59]. - The company reported a net increase in equity of 7,900,369.63 during the period[139]. Cash Flow and Assets - The net cash flow from operating activities showed a significant decline, with a net outflow of ¥84,888,400.90 compared to a net inflow of ¥21,192,688.41 in the same period last year, a decrease of 500.56%[19]. - Cash and cash equivalents at the end of the period amounted to ¥78,265,816.08, representing 5.56% of total assets, a decrease of 38.77% compared to the previous year[54]. - Accounts receivable increased to ¥185,089,787.36, accounting for 13.14% of total assets, reflecting a 40.61% increase due to higher revenue[54]. - Inventory stood at ¥282,949,415.33, which is 20.09% of total assets, showing a slight decrease of 2.13% from the previous year[54]. - The total assets at the end of the reporting period were ¥1,408,619,821.43, down 3.34% from ¥1,457,234,107.47 at the end of the previous year[19]. - The company's fixed assets totaled ¥554,319,048.33, accounting for 39.35% of total assets, with a decrease of 3.88% from the previous year[54]. Market Position and Strategy - The company is engaged in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, first aid kits, sports protection products, and nursing supplies[25]. - The company operates in the pharmaceutical manufacturing industry, specifically in the manufacturing of sanitary materials and pharmaceutical products[25]. - The company has established a strong market position in the medical device industry, leveraging ODM business models and increasing direct sales to achieve coordinated market development[36]. - The company is focusing on expanding its product range, particularly in high-end medical protective products like disposable gloves, to meet increasing market demands[46]. - The company plans to continue focusing on market expansion and new product development to drive future growth[128]. Research and Development - The company emphasizes technological research and development, collaborating with Zhejiang University to focus on innovative drug delivery technologies and skin penetration techniques[38]. - Research and development expenses amounted to RMB 14.82 million, a slight decrease of 0.22% compared to the previous year[45]. - The company holds a total of 11 invention patents, 38 utility model patents, and 9 design patents, enhancing its competitive edge in technology development[45]. Environmental and Compliance - The company has implemented measures to prevent water pollution, including connecting wastewater to a centralized treatment facility[75]. - The company is committed to complying with national environmental laws and regulations, enhancing environmental management practices[78]. - The company has not disclosed any other environmental information during the reporting period[79]. Shareholder and Governance - The company’s controlling shareholder, Li Ping, committed to not transferring more than 25% of his shares during his tenure and will not sell shares within six months after resignation[81]. - The company plans to repurchase at least 3% of its total shares within 90 days of the price stabilization announcement, with a repurchase price not exceeding 110% of the latest audited net asset per share[81]. - The company has committed to ensuring that measures to compensate for immediate returns are effectively implemented, protecting the interests of investors, especially small investors[82]. Legal and Risk Management - The company reported a litigation involving a contract dispute with Beijing Sentai Weiye International Trade Co., with a claim amount of RMB 545.10 million, and has recognized a bad debt provision of RMB 459.31 million[91]. - The company is exposed to product liability risks, which could harm its reputation and operational capabilities if unforeseen issues arise[65]. - The company faces risks from potential changes in national regulatory policies that could impact the competitive landscape of the pharmaceutical manufacturing industry[61]. Financial Reporting and Accounting - The financial statements are prepared based on the assumption of going concern, with sufficient operating funds for at least the next 12 months[166]. - The company adheres to the relevant accounting standards, ensuring that the financial statements accurately reflect its financial position and operating results[168]. - The company has not reported any significant changes in accounting policies or prior period error corrections during this reporting period[156].

你作为 ST 南卫控股股东，在向丰瑞达协议转让你所持有的股份时，未将对 收购方的主体资格、诚信情况及收购意图的调查情况在权益变动报告书中披露。 你的上述行为违反了《上市公司收购管理办法》(证监会令第 166 号)第三条、第 五十三条第一款和《公开发行证券的公司信息披露内容与格式准则第 15 号-权益 变动报告书》(证监会公告〔2020)20 号)第三十二条规定。 根据《上市公司收购管理办法》(证监会令第 166 号)第七十五条的规定，我 局决定对你采取出具警示函的监管措施，并记入证券期货市场诚信档案。你应当 严格遵守相关法律法规，切实履行信息披露义务，杜绝此类违规行为再次发生， 并于收到本决定书之日起 10 个工作日内向我局提交书面报告。 如对本监督管理措施不服，可以在收到本决定书之日起 60 日内向中国证券 监督管理委员会提出行政复议申请，也可以在收到本决定书之日起 6 个月内向有 证券代码：603880 证券简称：ST 南卫 公告编号：2023-073 江苏南方卫材医药股份有限公司 关于控股股东收到江苏证监局警示函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并 ...

证券代码：603880 证券简称：ST 南卫 公告编号：2023-072 江苏南方卫材医药股份有限公司 关于股票被实施其他风险警示相关事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、公司被实施其他风险警示的情况及进展 1、控制人及其控制的企业非经营性资金占用尚未偿还 南卫股份违反了《关于规范上市公司与关联方资金往来及上市公司对外担保若干 问题的通知》的相关规定，未按照《公司法》、《公司章程》以及《关联交易管理制 度》的相关规定就关联资金拆借行为履行董事会和股东大会等决策程序。南卫股份违 反了《上市规则》、《上市公司信息披露管理办法》、《信息披露事务管理制度》的 相关规定，未按要求对关联方资金拆借事项及时履行信息披露。南卫股份的内部控制 未能防止或及时发现并纠正上述违规行为，存在重大缺陷。截至2022年12月31日，南 卫股份未完成对上述重大缺陷的整改，应收实际控制人李平及其附属企业非经营性资 金占用款（含利息）4,335.49万元。 2、公司财务核算存在缺陷，导致前期会计差错更正 1 江苏南 ...

2023年6月3日,江苏南方卫材医药股份有限公司(以下简称ST南卫)发布了关于筹划控制权变更的公告(公告 编号:2023-039)。2023年6月15日,ST南卫发布公告称终止筹划本次控制权变更事项(公告编号:2023-055)。本次 筹划控制权转让过程中,你与苏州丰瑞达光电科技有限公司(以下简称丰瑞达)于2023年6月8日签订股权转让协 议,丰瑞达拟通过协议转让的方式受让你持有的上市公司2340万股股份(占上市公司股份总数的8.00%),同日披露 简式权益变动报告书。 你作为ST南卫控股股东,在向丰瑞达协议转让你所持有的股份时,未将对收购方的主体资格、诚信情况及收 购意图的调查情况在权益变动报告书中披露。你的上述行为违反了《上市公司收购管理办法》(证监会令第166 号)第三条、第五十三条第一款和《公开发行证券的公司信息披露内容与格式准则第15号-权益变动报告书》(证 监会公告〔2020〕20号)第三十二条规定。 | 索 | 引 | bm56000001/2023-00009621 号 | 分 | 类 | | | --- | --- | --- | --- | --- | --- | | | 发布机构 | 发 ...

证券代码：603880 证券简称：ST 南卫 公告编号：2023-071 江苏南方卫材医药股份有限公司 董事集中竞价减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董事持股的基本情况 一、集中竞价减持主体减持前基本情况 上述减持主体无一致行动人。 1 二、集中竞价减持计划的实施结果 (一)董事因以下事项披露集中竞价减持计划实施结果： 披露的减持时间区间届满 | 股东名称 | 减持数 | 减持 | 减持期间 | 减持方式 | 减持价格区间 | 减持总金 | 减持完成情况 | | 当前持股 | 当前持 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 量（股） | 比例 | | | （元/股） | 额（元） | | | 数量（股） | 股比例 | | 项琴华 | 54,000 | 0.02% | 2023/2/15～ | 集中竞价交易 | 6.30－6.35 | 340,584 | 未完成： ...

Financial Performance - The net profit attributable to shareholders for 2022 was -14,648,702.48 yuan, while the parent company achieved a net profit of 4,555,356.15 yuan[6]. - The total distributable profit for 2022, after considering the beginning retained earnings of 188,295,557.58 yuan, was 192,850,913.73 yuan[6]. - The company plans not to distribute profits or increase capital reserves for the year 2022 due to the negative net profit situation[7]. - The company's operating revenue for 2022 was approximately ¥545.37 million, representing a year-over-year increase of 3.40% compared to ¥527.44 million in 2021[23]. - The net profit attributable to shareholders of the listed company improved to approximately -¥14.65 million in 2022, a 35.64% increase from -¥22.76 million in 2021[23]. - The net cash flow from operating activities was approximately ¥31.28 million, a significant recovery from -¥84.25 million in 2021[23]. - Total assets increased by 17.98% to approximately ¥1.46 billion in 2022, up from ¥1.24 billion in 2021[24]. - Basic earnings per share improved to -¥0.05 in 2022, a 37.50% increase from -¥0.08 in 2021[25]. - The weighted average return on equity increased by 1.31 percentage points to -2.30% in 2022, compared to -3.61% in 2021[25]. - The company reported a total of ¥4.62 million in non-recurring gains in 2022, compared to -¥0.64 million in 2021[30]. Operational Highlights - The company achieved operating revenue of CNY 545.37 million in 2022, an increase of CNY 17.93 million compared to the previous year[32]. - The net profit attributable to shareholders was CNY -14.65 million, an improvement of CNY 8.11 million year-on-year[32]. - R&D expenses amounted to CNY 27.73 million, a decrease of 9.46% from the previous year, focusing on new topical formulations and technology upgrades[34]. - The company holds 24 Class I medical device registrations and 12 Class II registrations, with all main products certified by the FDA and TUV[35]. - The company completed the construction of a new medical adhesive dressing production project, with actual investment exceeding the planned amount by 2.24%[39]. - The company has developed a new multi-size, thickened nitrile glove that is favored in the labor protection market[37]. - The company is focusing on expanding its product categories in the medical device industry, particularly in high-end protective gloves[36]. - The company has established itself as a leading manufacturer of medical devices, particularly in the wound care sector, with a strong market influence after over 30 years of operation[46]. Market and Industry Trends - The global medical device market is projected to reach USD 532.8 billion in 2022, with a CAGR of 5.6% until 2024[88]. - The demand for disposable protective gloves is driven by health and safety awareness, with significant market potential in emerging markets[89]. - The domestic medical dressing industry is experiencing increasing concentration, benefiting larger enterprises as the demand for healthcare quality and safety rises[44]. - The regulatory environment for medical devices has strengthened, with new policies implemented to ensure safety and quality, creating a favorable landscape for domestic manufacturers[43]. - The company is positioned to benefit from the national centralized procurement reforms, which are becoming a new norm in the medical device industry[117]. Research and Development - The company has established a research and development center in collaboration with Zhejiang University, focusing on transdermal drug delivery technology and tissue regeneration[60]. - The company has applied for three national invention patents, which have all been accepted, indicating progress in innovation[60]. - The company has increased its investment in protective gloves R&D and fixed assets, resulting in the formation of technical achievements in 2022[96]. - The company is exploring the development of more emergency series products for various scenarios, including home, traffic accidents, and natural disasters[95]. - The company is focused on optimizing the adhesive properties of medical tapes to reduce skin irritation and enhance environmental benefits[95]. Governance and Compliance - The company has established a sound corporate governance structure, complying with relevant laws and regulations to support sustainable development[135]. - The company emphasizes investor relations, utilizing multiple channels to engage with investors and protect their interests[140]. - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with stakeholders[141]. - The company has implemented measures to manage risks associated with product liability and distributor management, which could impact sales[132][131]. - The company has not reported any significant differences in governance practices compared to regulatory requirements[142]. Financial Management and Strategy - The company aims to achieve an operating revenue of 700 million yuan and a profit of 30 million yuan in 2023, focusing on cost control and enhancing profitability[119]. - The company intends to enhance its financial management by reducing the debt-to-asset ratio and improving the efficiency of resource utilization[122]. - The company has a cash dividend policy that mandates a minimum of 25% of distributable profits to be distributed as cash dividends when conditions allow[165]. - The company has established a profit distribution plan that requires the board of directors to propose and draft based on the company's articles of association, profitability, and funding needs[166]. - The company has committed to rectifying the identified internal control deficiencies and has already received repayment of occupied funds from related parties[177]. Environmental and Social Responsibility - The company invested approximately 14.33 million yuan in environmental protection during the reporting period[180]. - The company operates 2 natural gas boilers with an annual consumption of 1.5 million cubic meters of natural gas, meeting emission standards for pollutants[182]. - The company has implemented measures to prevent noise pollution, ensuring compliance with the GB12348-2008 standards for industrial enterprises[183]. - The company made a total donation of 100,000 yuan for public welfare projects[186]. Shareholder and Management Information - The total shareholding of senior management at the beginning of the year was 12,829.13 million shares, which decreased to 12,823.13 million shares by the end of the year, reflecting a reduction of 6 million shares[144]. - The total pre-tax remuneration for senior management during the reporting period amounted to 251.42 million yuan[144]. - The company has a diverse management team with extensive experience across various sectors, enhancing its operational capabilities[146]. - The company is focused on maintaining stability in its shareholding structure while ensuring competitive remuneration for its executives[144].

Financial Performance - In 2021, the company's total revenue was ¥527,440,662.01, a decrease of 50.82% compared to ¥1,072,399,917.76 in 2020[21] - The net profit attributable to shareholders of the listed company for 2021 was -¥22,762,007.90, compared to a profit of ¥98,067,613.55 in 2020[21] - The net cash flow from operating activities was -¥84,252,019.54 in 2021, a significant decline from ¥154,122,592.63 in 2020[21] - The net assets attributable to shareholders of the listed company at the end of 2021 were ¥649,784,562.92, down 6.75% from ¥696,791,263.63 at the end of 2020[21] - The company reported a total revenue of 527.44 million yuan in 2021, a decrease of 54.50 million yuan compared to the previous year[30] - The net profit attributable to shareholders was -22.76 million yuan, a decrease of 120.83 million yuan year-on-year[30] - Basic earnings per share were -0.0778 yuan, down from 0.3426 yuan in 2020[23] - The weighted average return on equity decreased by 19.43 percentage points to -3.42%[23] - The gross profit margin for the industrial sector was 20.71%, down 13.16 percentage points from the previous year[69] - The company achieved operating revenue of 527.44 million yuan, a decrease of 54.50 million yuan compared to the same period last year[64] Corporate Governance - The company held 5 shareholder meetings and 12 board meetings to strengthen corporate governance[30] - A board and supervisory committee election was conducted in December 2021 to enhance governance structure[31] - The company emphasizes investor relations, maintaining communication with shareholders and stakeholders to protect their interests and enhance company value[146] - The company adheres to strict information disclosure practices, ensuring transparency and compliance with relevant regulations[147] - The company has implemented measures to manage insider information and maintain confidentiality, complying with regulatory requirements[148] - The company held 12 board meetings in the year, with 4 conducted in person and 8 combining in-person and communication methods[157] - The company has a clear mechanism for profit distribution decision-making, requiring board approval and shareholder meeting validation[173] - The company has established a robust internal control management system in compliance with regulatory requirements, enhancing decision-making efficiency and ensuring asset safety[178] Research and Development - The company invested CNY 30.623 million in R&D during the reporting period, a decrease of 9.83% compared to the previous year, focusing on new topical formulations and technology upgrades[33] - The company emphasizes technology research and development, focusing on transdermal drug delivery technology improvements and stem cell-based tissue regeneration[58] - The company has established a "New Transdermal Preparation Research Center" in collaboration with Zhejiang University to enhance its R&D capabilities[58] - The company added 4 invention patents and 9 utility model patents during the reporting period, totaling 11 invention patents and 33 utility models[94] - Major R&D projects included foam tape (2.42 million RMB, -26.36% YoY), breathable tape (2.58 million RMB, -43.73% YoY), and antibacterial masks (2.12 million RMB, -26.77% YoY)[103] Market Strategy and Expansion - The company is expanding its product line by adding a high-end medical glove production line, particularly focusing on nitrile gloves due to their superior protective qualities and market growth potential[34] - The company plans to continue expanding its market share and production capacity to lay a solid foundation for future domestic market growth[34] - The company is focusing on expanding its own brand products, particularly in first aid kits, protective gear, and nursing supplies, to enhance market presence[56] - The company is exploring market expansion opportunities and potential mergers and acquisitions to strengthen its competitive position[120] - The company plans to issue convertible bonds and has outlined a shareholder return plan for the next three years (2021-2023)[149] Environmental Responsibility - The company has implemented measures to prevent environmental pollution, including wastewater treatment and waste gas emission controls, meeting national standards[183] - The company uses clean energy sources, such as natural gas, for its operations, significantly reducing emissions[184] - The company has developed an emergency response plan for environmental incidents, enhancing its capability to manage potential environmental risks[185] - The company has committed to environmental responsibility, although specific measures for carbon emission reduction were not disclosed[187] Employee Management and Development - The company emphasizes the importance of employee training, focusing on legal regulations, professional skills, and management capabilities[170] - The company has a cash dividend policy that mandates a minimum of 25% of distributable profits to be distributed as cash dividends when conditions allow[172] - Employee wages have been steadily increased, with the company providing social insurance and housing funds for all employees[188] - The company has no outsourced labor arrangements, indicating a fully in-house workforce[171] Financial Management - The company is committed to enhancing shareholder value through strategic financial management and operational excellence[151] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.4094 million yuan[153] - The company has implemented a stock buyback program, resulting in a reduction of 19.06 million shares[151] - The company is strengthening its financial management to lower the debt-to-asset ratio and improve operational efficiency[127] Risks and Challenges - The company reported a negative net profit for the first time, indicating potential challenges in its business strategy and market conditions[4] - The company faced risks related to product liability, litigation, and arbitration, which could potentially damage its reputation and operational capacity[135] - The COVID-19 pandemic has impacted the company's operations, including production, procurement, and market sales, with significant uncertainty regarding the future of its pandemic-related protective product lines[137]

Financial Performance - The company's operating revenue for 2020 reached ¥1,072,399,917.76, representing a 118.11% increase compared to ¥491,688,011.57 in 2019[20] - The net profit attributable to shareholders of the listed company was ¥98,067,613.55, a significant increase of 249.60% from ¥28,051,595.53 in the previous year[20] - The net profit after deducting non-recurring gains and losses was ¥86,701,465.59, up 275.58% from ¥23,084,715.39 in 2019[20] - The net cash flow from operating activities was ¥154,122,592.63, a 367.12% increase from ¥32,994,069.13 in 2019[21] - As of the end of 2020, the total assets amounted to ¥1,072,645,455.80, reflecting a 23.35% increase from ¥869,601,971.34 in 2019[21] - The net assets attributable to shareholders of the listed company were ¥696,791,263.63, which is a 23.51% increase compared to ¥564,157,337.40 at the end of 2019[21] - Basic earnings per share increased by 164.71% to CNY 0.45 in 2020 compared to CNY 0.17 in 2019[22] - The weighted average return on equity rose to 16.01%, an increase of 10.99 percentage points from 5.02% in 2019[22] - The company reported a net profit of CNY 9,432,898.99 for Q1 2020, reflecting a strong performance despite the pandemic[25] Dividend and Profit Distribution - The company plans to distribute a cash dividend of ¥1.5 per 10 shares, totaling approximately ¥33,777,000.00, and to increase the share capital by 3 shares for every 10 shares held[5] - The company has a cash dividend policy that mandates at least 25% of distributable profits to be distributed as cash dividends when conditions allow[144] - The company’s cash dividend distribution policy varies based on its development stage, with a minimum cash dividend of 80% for mature stages without major capital expenditures[144] - The company’s profit distribution plan for 2020 is subject to approval at the annual shareholders' meeting[148] - The company’s profit distribution proposal includes a capital reserve increase of 3 shares for every 10 shares held[147] - The company emphasizes the importance of maintaining a stable and continuous profit distribution policy to ensure reasonable returns for investors[143] Research and Development - R&D expenses amounted to 33.96 million yuan, reflecting a 52.30% increase year-on-year, focusing on new external preparations and transdermal drug delivery technology[61] - The company holds a total of 30 Class I medical device registrations and 14 Class II medical device registrations as of the end of the reporting period[62] - The company has obtained two national invention patents related to new external preparations for treating diabetic chronic ulcers and a new combination permeation agent[49] - The company is focusing on the R&D of hydrogel formulations and light-curing adhesives for transdermal drug delivery technology[99] - Major R&D projects included antibacterial medical bandages with an investment of RMB 3,771,980.69, accounting for 0.35% of revenue, showing a year-on-year increase of 37.31%[109] Market Position and Industry Overview - The company has established a strong market position in the medical device industry, leveraging nearly 30 years of operational experience and the cluster effect of the textile industry in the Yangtze River Delta[46] - The medical device market is expected to continue growing, driven by increased health awareness and government policies[92] - The company’s industry exhibits strong demand characteristics, showing resilience against macroeconomic fluctuations, indicating a lack of significant cyclicality[44] - The medical device industry in China remains fragmented, with many companies relying on traditional products and facing intense competition[125] Operational Efficiency and Production - The company has enhanced its production efficiency through automation and process improvements, leading to a reduction in production costs[61] - The production model is "sales-driven production," where production is organized based on customer demand, ensuring timely preparation of necessary raw materials for large clients[38] - The company is actively expanding its production capacity for various protective products while maintaining existing product sales[63] - The company primarily produces protective equipment, including daily protective masks, disposable medical masks, and surgical masks, catering to both the general public and healthcare professionals[36] Risks and Challenges - The company emphasizes that forward-looking statements do not constitute a commitment to investors and advises caution regarding potential risks[6] - The company faces risks from industry policy changes that could impact its operations and market competition[135] - The company is exposed to intensified market competition, particularly in the low-end medical device sector[136] - The company is at risk from fluctuations in foreign exchange rates, which could affect its export revenue and overall performance[138] Corporate Governance and Shareholder Rights - The company’s independent directors are involved in reviewing and providing opinions on the profit distribution proposals[145] - The controlling shareholder and actual controller, Li Ping, committed not to transfer or entrust the management of shares held directly or indirectly for 36 months from the date of the company's stock listing[152] - The company has committed to measures to ensure the filling of immediate returns that may be diluted by the initial public offering[156] - The company committed to optimizing investor returns and ensuring the protection of small investors' rights[157] Environmental and Social Responsibility - The company has established a social responsibility management system to enhance its sense of social responsibility[182] - The company utilizes clean production processes and has established measures to prevent water and air pollution, including the use of natural gas for boilers[187] - The company has a structured approach to waste management, ensuring hazardous waste is handled by qualified entities[188] - The company has established a long-term donation mechanism with local charity organizations to fulfill its social responsibilities[184] Legal Matters and Litigation - There are ongoing significant litigation matters involving equity transfer disputes, with updates disclosed in multiple announcements throughout the year[167] - The company has faced a lawsuit regarding a procurement contract for 35,000 masks, with a claim amounting to 514,150 RMB[168] - The company has incurred legal fees of 160,000 yuan related to ongoing litigation[172] - The company has requested the court to confirm the termination of a procurement contract and to order the return of 4,660,000 yuan in unpaid funds[172]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 226,130,904.54, representing a year-on-year increase of 58.09%[5] - The net profit attributable to shareholders of the listed company was CNY 6,930,672.43, an increase of 3.03% compared to the same period last year[5] - The net profit for Q1 2023 was CNY 6,911,204.99, an increase from CNY 6,601,990.71 in Q1 2022, representing a growth of approximately 4.67%[18] - Operating profit for Q1 2023 was CNY 7,919,872.69, compared to CNY 7,439,759.53 in the same period last year, indicating an increase of about 6.45%[18] - Total revenue from operating activities reached CNY 296,570,290.27, significantly up from CNY 124,379,187.30 in Q1 2022, marking an increase of approximately 138.06%[19] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 20,595,515.00, with the increase attributed to higher sales and collections[8] - The cash flow from operating activities showed a net inflow of CNY 20,595,515.00, a recovery from a net outflow of CNY 25,084,420.24 in the previous year[20] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 142,900,250.05, up from CNY 72,403,784.09 at the end of Q1 2022, indicating an increase of about 97.06%[20] - Cash and cash equivalents as of March 31, 2023, amounted to ¥147,126,389.89, compared to ¥127,818,267.43 at the end of 2022, representing a growth of 15.5%[14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,490,102,502.58, up 2.26% from the end of the previous year[6] - Total liabilities increased to ¥856,041,522.47 in Q1 2023 from ¥835,750,892.20 in Q4 2022, showing a rise of 2.0%[15] - The company’s total assets impairment loss was CNY 2,108,279.06, compared to a gain of CNY 468,905.11 in Q1 2022, indicating a significant change in asset valuation[18] Shareholder Information - The company had a total of 15,707 common shareholders at the end of the reporting period[10] - Major shareholder Li Ping held 40.63% of the shares, with 74,188,784 shares pledged[10] Costs and Expenses - Total operating costs for Q1 2023 were ¥226,511,378.39, up from ¥137,739,528.05 in Q1 2022, reflecting an increase of 64.2%[16] - The company incurred financial expenses of CNY 2,391,515.19 in Q1 2023, down from CNY 4,299,454.46 in Q1 2022, representing a decrease of approximately 44.34%[18] - Research and development expenses for Q1 2023 were CNY 8,313,881.01, up from CNY 7,271,150.60 in Q1 2022, reflecting an increase of about 14.34%[18] Market and Growth Strategy - The increase in operating revenue was primarily driven by the sales of protective products[8] - The company is focusing on expanding its market presence and developing new products to enhance future growth prospects[16] Equity and Returns - Basic and diluted earnings per share were both CNY 0.024, reflecting a year-on-year increase of 4.35%[6] - The weighted average return on equity was 1.06%, a slight increase of 0.03% compared to the previous year[6] - The company reported a decrease of 1.04% in net profit after deducting non-recurring gains and losses, amounting to CNY 6,497,021.61[5] - The company reported a net loss for Q1 2023, with total costs exceeding total revenue, indicating challenges in profitability despite revenue growth[16]